Når unormale laboratorieværdier og bivirkninger blev slået sammen på tværs af konkomitante og monoterapi behandlingsfaser, blev Grad 3 - eller Grad 4- neutrofilabnormaliteter inklusive neutropeni- bivirkninger set hos 8% af patienterne.
When laboratory abnormalities and adverse events were combined across concomitant and monotherapy treatment phases, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic events were observed in 8% of the patients.